SEARCH

Current Edition

blood

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat …

Continue Reading →
cancer

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form …

Continue Reading →
cancer

Roche’s top immunotherapy prospect fails study in tough-to-treat lung cancer

Dive Brief: A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for …

Continue Reading →
drugmakers

FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a common …

Continue Reading →
Biotech

Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

Dive Brief: Shares in Nektar Therapeutics fell by more than half Monday morning after the San Francisco biotech company and partner Bristol Myers Squibb disclosed …

Continue Reading →
cancer

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed …

Continue Reading →
clinical trial

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could …

Continue Reading →
cervical cancer

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck’s Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that’s cleared for use in cervical …

Continue Reading →
AstraZeneca

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials …

Continue Reading →
ArQule

Merck wins approval for cancer drug acquired in 2019 biotech buyout

Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda with …

Continue Reading →
advances

Immunotherapy advances spur new look at cancer vaccines

In an era of cancer immunotherapy, vaccines are getting fresh consideration as a therapeutic approach. Frustrated for years by lackluster results, cancer vaccine research is …

Continue Reading →